A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study Article

Robins, H Ian, Zhang, Peixin, Gilbert, Mark R et al. (2016). A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study . JOURNAL OF NEURO-ONCOLOGY, 126(2), 309-316. 10.1007/s11060-015-1966-z

Open Access

cited authors

  • Robins, H Ian; Zhang, Peixin; Gilbert, Mark R; Chakravarti, Arnab; de Groot, John F; Grimm, Sean A; Wang, Fen; Lieberman, Frank S; Krauze, Andra; Trotti, Andy M; Mohile, Nimish; Kee, Andrew YJ; Colman, Howard; Cavaliere, Robert; Kesari, Santosh; Chmura, Steven J; Mehta, Minesh

sustainable development goals

authors

publication date

  • January 1, 2016

published in

keywords

  • ABT-888
  • ADJUVANT TEMOZOLOMIDE
  • ALKYLTRANSFERASE
  • CONCOMITANT
  • Clinical Neurology
  • Glioblastoma
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • PROGRESSION
  • RADIOTHERAPY
  • Science & Technology
  • TRIAL
  • Temozolomide
  • Velparib

Digital Object Identifier (DOI)

publisher

  • SPRINGER

start page

  • 309

end page

  • 316

volume

  • 126

issue

  • 2